Dicerna Pharmaceuticals Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene, a Key Cancer Regulator
3/19/2013 10:09:55 AM
More...
|
Dicerna Pharmaceuticals Announces That Kyowa Hakko Kirin Has Selected a Second DsiRNA Therapeutic Candidate for Development, Triggering $5 Million Milestone Payment
1/3/2013 9:47:23 AM
More...
|
Dicerna Pharmaceuticals Presents Data on RNAi Therapeutic Programs at the International Liver Cancer Association (ILCA) Sixth Annual Conference
9/17/2012 10:19:17 AM
More...
|
Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone
8/9/2012 10:43:44 AM
More...
|
Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone
8/8/2012 10:28:47 AM
More...
|
Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer
1/4/2012 7:27:07 AM
More...
|
Dicerna Pharmaceuticals Announces First DsiRNA Therapeutic Candidate Selected for Development, Triggering $5 Million Milestone Payment
12/15/2011 7:09:42 AM
More...
|
Dicerna Pharmaceuticals Awarded Notice of Allowance by U.S. Patent and Trademark Office for Patent Claims Broadly Covering Dicer Substrate siRNA Molecules
11/1/2011 7:23:09 AM
More...
|
Dicerna Pharmaceuticals to Present at Upcoming Conferences
2/28/2011 9:28:16 AM
More...
|
Dicerna Pharmaceuticals Expands Pact Kyowa Hakko Kirin; Original Agreement Worth $1.4 Billion Potentially
12/7/2010 7:33:39 AM
More...
|
|